Patient Outcomes and Cost Effects of Medicaid Formulary Restrictions on Antidepressants
Gustafson Thomas and
Additional contact information
Walter Deborah: Takeda Pharmaceuticals America, Inc., Washington, DC, USA
Hayes John: National Network of Depression Centers, Ann Arbor, MI, USA
Gustafson Thomas: Arnold and Porter, LLP, Washington, DC, USA
Shrestha Anshu: Precision Health Economics, Los Angeles, CA, USA
Forum for Health Economics & Policy, 2014, vol. 17, issue 2, 16
Many state Medicaid programs have implemented policies designed to reduce spending on prescription drugs by restricting access to branded products. For patients with major depressive disorder, formulary restrictions could severely limit access to antidepressant therapies and disrupt care. We linked data on patient outcomes and spending from 24 state Medicaid programs to information on formulary restrictions from 2001 to 2008. Outcomes included frequency of MDD-related hospitalizations and ER visits per patient and total healthcare spending. We estimated the effect of the policies on patient outcomes and spending using a difference-and-difference approach. We found that restricting access to antidepressants increased the probability of an MDD-related hospitalization by 1.7 percentage points (16.6%). Furthermore, we found no evidence that these restrictions resulted in any net savings for Medicaid.
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1) Track citations by RSS feed
Downloads: (external link)
https://www.degruyter.com/view/j/fhep.2014.17.issu ... -0016.xml?format=INT (text/html)
For access to full text, subscription to the journal or payment for the individual article is required.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:bpj:fhecpo:v:17:y:2014:i:2:p:16:n:4
Ordering information: This journal article can be ordered from
Access Statistics for this article
Forum for Health Economics & Policy is currently edited by Dana Goldman
More articles in Forum for Health Economics & Policy from De Gruyter
Bibliographic data for series maintained by Peter Golla ().